Women proved equally likely to complete the full 48 weeks of the trial
For the rationale behind this ladder over a dual-agonist comparator, see retatrutide vs semaglutide vs tirzepatide
Who Benefits and Who Should Avoid Lip C Therapy Lip C injection may be considered for patients with confirmed metabolic slowing, fatty liver disease, or metabolic syndrome seeking adjunctive metabolic support under medical supervision
As more patients arrive having researched therapies with AI, physicians will need to spend as much time discussing the quality of the evidence as the proposed mechanism.
Elman MJ, Bressler NM, Qin H, et al
And finally, lipomatosis like that of FML has also been reported in two cases after chemotherapy (161,162), a treatment known to be associated with an increased risk of cancer development